Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...
Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
US pharma giant Pfizer has announced positive results from the Phase III TALAPRO-2 study of Talzenna (talazoparib), an oral ...
Pfizer (PFE) announced results from the Phase 3 TALAPRO-2 study of TALZENNA, an oral poly ADP-ribose polymerase inhibitor, in combination with ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, ...
Astrobiologists in Germany are developing a new testing device that could help tease dormant alien microbes into revealing ...
Tumor immune evasion mechanisms could be reversed by activating intracellular antiviral immune responses. It has been reported that the use of DNA methyltransferase (DNMT) inhibitors combined with ...
The loss of endothelial function precedes these vascular alterations. Here we report that activation of poly(ADP-ribose) polymerase (PARP) is an important factor in the pathogenesis of endothelial ...
Scientists have found all five nucleobases alongisde minerals essential for life as we know it on the potentially hazardous ...
Got a tip? Send it to The Daily Beast here. ADVERTISEMENT ADVERTISEMENT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback